AI appetite slows as clinical trial leaders refocus on risk-based strategies

Diane Lacroix, Vice President of Clinical Data Management, eClinical Solutions

eClinical’s 2025 Industry Outlook reveals cracks in tech hype—and fresh momentum behind smarter processes

The clinical research industry’s enthusiasm for artificial intelligence (AI) appears to be maturing, with fewer organizations in the exploratory phase and a growing number reporting stalled or scaled-back ambitions.

That’s one of the more revealing takeaways from eClinical Solutions’ 2025 Industry Outlook, an annual survey of clinical data leaders across pharma, biotech, and CROs. While the majority—72%—say they’re either using or planning to use AI across multiple areas, a surge in those with no plans to adopt it suggests some disillusionment is setting in.

Instead, attention appears to be shifting toward risk-based strategies that prioritize quality and compliance while mitigating trial delays. Nearly twice as many respondents as last year cited these approaches as having the greatest potential to improve trial efficiency and outcomes in 2025.

Raj Indupuri, CEO and co-founder of eClinical Solutions, says it’s a sign that organizations are thinking more holistically. “AI can drive the next wave of innovation, but not without the right ecosystem,” he said. “It’s not just about algorithms—it’s about building a data and analytics infrastructure that enables people to make decisions faster and smarter.”

Beyond the buzz

The data suggests a more pragmatic view of AI is taking hold. While interest remains high, challenges persist—and not necessarily where expected. Of those actively using or exploring AI, 98% reported facing barriers, with an average of 2.5 problem areas per organization. These are less about the capabilities of the technology itself and more about navigating compliance, securing data privacy, and demonstrating ROI.

At the same time, just 33% of respondents rated their current technology stack as highly effective in managing risk, revealing a significant gap between digital ambition and operational reality.

Data access and outsourcing pain points

Across the board, real-time access to data remains a pressing issue, with 59% saying it’s a top priority for their clinical teams. Yet infrastructure limitations and partner performance are slowing progress.

Around 75% of organizations outsource data management to CROs or vendors—but dissatisfaction is common. More than 80% of respondents said their partners fall short when it comes to delivering timely insights and proposing innovative solutions. Issues cited include missed timelines, lack of experienced professionals, and subpar data outputs.

According to Diane Lacroix, VP of clinical data management at eClinical Solutions, the industry is at a pivotal moment. “Life sciences leaders are overwhelmed by data complexity, and many are still stuck in outdated workflows,” she said. “What they need from partners is not more dashboards—they need real, operational intelligence that helps them move faster and with more confidence.”

Looking ahead

The report paints a picture of an industry in transition—one where AI is no longer seen as a silver bullet, and success will hinge on more than tech. Real innovation, the data suggests, will come from organizations that take a layered approach: strengthening partnerships, investing in people and processes, and applying digital tools with clear intent.

As the pressure to deliver faster, more efficient trials grows, the question is no longer if the industry will transform—but how ready each player is to lead the charge.atients faster.”